Statistics from Altmetric.com
We appreciate the interest and comments by Dr Ma and colleagues1 on our recent publication.2 Not surprisingly, our study results differ from their previous study.3 We agree with their point regarding the differences in the definition of the main study outcome and the International Classification of Diseases (ICD) codes used to define them and discussed it in our paper.2 We examined the incidence of hypersensitivity reactions using two previously published validated algorithms by Strom et al and Wright et al compared with their ICD algorithms to define cutaneous hypersensitivity reactions;3 we are unable to locate the accuracy statistics of their algorithms in this publication. Differences in study findings with regard to the risk of these adverse outcomes with allopurinol and febuxostat indicate that in future studies, both types of definitions (ours and theirs) need to be examined simultaneously. This would make the study results robust and allow a more definitive answer to the question: is the risk of all hypersensitivity reactions, or all cutaneous hypersensitivity reactions, or severe cutaneous hypersensitivity reactions, different for allopurinol-exposed versus febuxostat-exposed populations?
We respectfully disagree with their comment that allopurinol-associated hypersensitivity reactions would have been attributed to febuxostat in error, since patients likely started febuxostat after stopping allopurinol. We required a >30-day period between prescription fills, for the definition of a new allopurinol (or febuxostat or colchicine) prescription start to avoid the issue of misattribution. This 30-day period also accounted for any residual biological effects of medications. Misclassification is always possible; however, we likely minimised it with the use of this approach.
We agree that a lot of patients may be concurrently using non-steroidal anti-inflammatory drugs (NSAIDs), which are known to be associated with hypersensitivity reactions. This could have confounded findings from all epidemiological studies to-date including our study, since most NSAIDs are available over-the-counter in most countries and could not be accounted for in any study so far. The hypersensitivity reactions seen with colchicine in our study might indicate the concomitant use of other medications (NSAIDs) not captured in our analyses; they are equally likely to be due to concomitant use of medications used for other disorders (cardiovascular disease, infections; ACE inhibitors, antibiotics, antivirals, anticonvulsants),4 5 subclinical undiagnosed chronic conditions (not captured in Deyo-Charlson comorbidity index), drug-drug interactions and drug-disease interactions6 that are very common in the elderly. Importantly, we are reporting associations, not causality. Establishing causality is difficult with observational studies.
We discuss and agree that the incidence of (and susceptibility to) hypersensitivity reactions likely varies by the country setting,2 related to differences in the HLA-B*5801 allele frequencies. Analysis of severity of hypersensitivity reactions was not a study objective. Standardised documentation using scoring systems as they note in their letter can also allow for a better understanding of these outcomes in the future. The almost universal use of electronic health records should make this possible in the future.
Handling editor Josef S Smolen
Author contributions: JAS wrote the first manuscript draft, revised, read and approved the final version.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Trio health, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, Practice Point communications, the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics. JAS is on the speaker’s bureau of Simply Speaking. JAS is a member of the executive of OMERACT, an organisation that develops outcome measures in rheumatology and receives arms-length funding from 12 companies. JAS serves on the FDA Arthritis Advisory Committee. JAS is the chair of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS previously served as a member of the following committees: member, the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee. There are no non-financial competing interests for any of the authors.
Patient consent for publication Not required.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.